Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Óðîëîãèÿ è àíäðîëîãèÿ > Ìóæñêîå áåñïëîäèå

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 12.07.2012, 18:53
Andrii_Z Andrii_Z âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 03.06.2012
Ãîðîä: Kyiv
Ñîîáùåíèé: 21
Andrii_Z *
L-êàðòíèòèí è âèòàìèí E

Ñòîèò ëè âåðèòü êèòàéöàì?

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

One of the important reasons for male infertility is asthenozoospermia, for which there is no specific cure for the time being. The authors explored the clinical effect of L-carnitine for infertile males with asthenozoospermia.
METHODS:

A total of 135 patients with asthenozoospermia were randomly divided into Groups A (n = 68) and B (n = 67), the former treated with L-carnitine (2 g/d) and vitamin E, while the latter with vitamin E only, both for 3 months. All the patients received semen analyses before and after the treatment, and were observed for adverse effects. The pregnancy rates of their wives were recorded.
RESULTS:

Group A showed a significantly increased percentage of forward motile sperm after the treatment (45.4% +/- 11.1%) as compared with pretreatment (28.6% +/- 9.2%) (P < 0.01), but no statistically significant differences were found in sperm density and the percentage of the sperm of normal morphology (P > 0.05). The rate of pregnancy was significantly higher in Group A (31.1%) than in B (3.8%) after the treatment (P < 0.01). No adverse events were found during the treatment.
CONCLUSION:

L-carnitine, capable of significantly improving sperm motility and raising the rate of pregnancy, is a safe and effective therapeutic option for asthenozoospermia.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 12.07.2012, 18:59
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,285
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,625 ðàç(à) çà 32,699 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ìåíÿ êóäà áîëüøå èíòåðåñóåò âîïðîñ- íàäî ëè îáûâàòåëÿ ó÷èòü ïðàâèëàì îöåíêè êà÷åñòâà íàó÷íîé ïóáëèêàöèè íà ìåäèöèíñêèå òåìû ?
Âîïðîñû æå âåðû íå îáñóæäàþòñÿ íà ìåäèöèíñêèõ ôîðóìàõ
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 12.07.2012, 19:06
Andrii_Z Andrii_Z âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 03.06.2012
Ãîðîä: Kyiv
Ñîîáùåíèé: 21
Andrii_Z *
Íóæíî, êîíå÷íî.
Îáúÿñíèòå ìíå, ÷òî òàê è íå òàê ñ ýòèì èññëåäîâàíèåì.

Ñíà÷àëà ÿ íàøåë èññëåäîâàíèå ïî âèòàìèíó E, íî îíî ÿâíî ñëàáåíüêîå áûëî, ïî 29 îñîáàì. Òóò âðîäå áû äîñòàòî÷íîå êîëè÷åñòâî, íî íå ñêàçàíî, ÷òî îíî á³ëî ñëåïûì, òàê ÷òî êàê-òî ñîìíèòåëüíî.

À âåðà, êîíå÷íî, ýòî ïðîñòî ôèãóðà ðå÷è — ÿ õîòåë ñïðîñèòü, ÷òî äîêàçûâàåò (èëè íå äîêàçûâàåò) òàêîå èññëåäîâàíèå? ß ïîíèìàþ, ÷òî îäíî èññëåäîâàíèå âîîáùå íè÷åãî íå äîêàçûâàåò, åñòü ëè äðóãèå èññëåäîâàíèÿ íà ýòó òåìó.
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 12.07.2012, 19:39
Andrii_Z Andrii_Z âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 03.06.2012
Ãîðîä: Kyiv
Ñîîáùåíèé: 21
Andrii_Z *
Èëè âîò
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia.

RESULT(S):

Sperm cell motility (total and forward, including kinetic features determined by computer-assisted sperm analysis) increased in patients to whom LAC was administered both alone or in combination with LC; combined LC + LAC therapy led to a significant improvement of straight progressive velocity after 3 months. The total oxyradical scavenging capacity of the semen toward hydroxyl and peroxyl radicals also increased and was positively correlated with the improvement of kinetic features. Patients with lower baseline values of motility and total oxyradical scavenging capacity of the seminal fluid had a significantly higher probability of responding to the treatment.
CONCLUSION(S):

The administration of LC and LAC is effective in increasing sperm kinetic features in patients affected by idiopathic asthenozoospemia and improves the total oxyradical scavenging capacity of the seminal fluid in the same population.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 12.07.2012, 19:45
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,285
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,625 ðàç(à) çà 32,699 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðèâåäåííûå Âàìè ïóáëèêàöèè óêàçûâàþò íà íàëè÷èå ïèëîòíûõ ïðîåêòîâ ïî èçó÷åíèè âîçìîæíîñòåé èñïîëüçîâàíèÿ êàðíèòèíà - èñïîëüçóÿ àíàëîãèþ Ìàðêà Òâåíà , ïîäîáíûå ìîëèòâû ìû ñîáèðàåì â åäèíûé ïóë è èñïîëüçóåì äëÿ îãðàíè÷åíèÿ äîñòóïà ãðåøíèêîâ ( öèò ïî ïàìÿòè )
Ïåðåâîäÿ íà ïðèíÿòûé â ìåäèöèíå ÿçûê- ýêñïåðòû îöåíèâàþò ñîâîêóïíûå äàííûå ïîäîáíûõ ïóáëèêàöèé è óðîâåíü äîêàçàòåëüíîñòè è â äàëüíåéøåì ðåêîìåíäóþò / íå ðåêîìåíäóþò â øèðîêóþ ïðàêòèêó
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 12.07.2012, 19:48
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,412
Ïîáëàãîäàðèëè 33,243 ðàç(à) çà 31,592 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ïî êàðíèòèíó íå ìåíåå 20 èññëåäîâàíèé áûëî ïðè ìóæñêîì áåñïëîäèè: ïîõîæå, åòó òåìó ïîäíÿëè èòàëüÿíöû - â èõ ðóêàõ êàðíèòèí ìîã áû áûòü ïîòåíöèàëüíî ïðèìåíåí ñ óñïåõîì, îñîáåííî åñëè êàêèå-òî ïîêàçàòåëè ñïåðìîãðàììû áûëè èçíà÷àëüíî ñíèæåíû, äàëåå òåñòèðîâàëè àìåðèêàíöû - áåçóñïåøíî, ïîòîì êèòàéöû, æèòåëè áëèæíåãî âîñòîêà - ó íèõ âñåãäà óñïåõ... ñòîèò ëè Âàì íà ñåáå åòî ïðîáîâàòü - ðåøèòå äëÿ ñåáÿ ñàìè... îòñóòñòâèå èññëåäîâàíèé èç öèâèëèçîâàííûõ ñòðàí èëè îòñóòñòâèå åôôåêòà, íî âñåãäà ïîëîæèòåëüíûå ðåçóëüòàòû, ãäå êà÷åñòâî èññëåäîâàíèé ìîæåò õðîìàòü, íàâåâàåò ìûñëè íà ïîòåíöèàëüíî çàêàçíîé/ïðåäâçÿòûé õàðàêòåð ïîñëåäíèõ ïóáëèêàöèé
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 12.07.2012, 19:55
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,412
Ïîáëàãîäàðèëè 33,243 ðàç(à) çà 31,592 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
åñëè Âàì èíòåðåñåí ìíåíèå ñïåöèàëèñòîâ ïî äàííîìó âîïðîñó - ïî÷èòàéòå ñåé îïóñ:

Oxidative stress and antioxidants for idiopathic oligoasthenoteratospermia: Is it justified?

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #8  
Ñòàðûé 12.07.2012, 20:08
Andrii_Z Andrii_Z âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 03.06.2012
Ãîðîä: Kyiv
Ñîîáùåíèé: 21
Andrii_Z *
Îñîáåííî ïîíðàâèëîñü
Unfortunately, many drugs are currently used without any rationale: such therapies are often prescribed sequentially without any beneficial effect, and any improvements that do occur in semen parameters may be due to other unrelated reasons.
Êîðî÷å, ê íàøèì ýñêóëàïàì ëó÷øå âîîáùå íå ñîâàòüñÿ.
À âîò èíòåðåñíî, íà ïðîñòîðàõ ýêñÑÑÑÐ, êòî íèáóäü åñòü íà íàó÷íîì ôðîíòèðå ïî èññëåäîâàíèÿì ìóæñêîãî áåñïëîäèÿ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #9  
Ñòàðûé 12.07.2012, 20:15
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,285
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,625 ðàç(à) çà 32,699 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íà ïðîñòîðàõ åñòü âñå äëÿ ñðàâíèòåëüíî ÷åñòíîãî ñïîñîáà îòúåìà äåíåã , ÷òî æå êàñàåòñÿ íàó÷íûõ èññëåäîâàíèé , òî .. ñì íà÷àëî îòâåòà íà âîïðîñû
È êîíòâîïðîñ - à ïî÷åìó âû èçáèðàòåëüíî öèòèðîâàëè ëèòåðàòóðó èç îäíîãî èç ñàìûõ ïðîñòûõ èñòî÷íèêîâ ïîëó÷åíèÿ èíôîðìàöèè ?
Âû ïëàíèðîâàëè îáó÷åíèå âðà÷åé ? Òàê ñêàçàòü , ìàëîñòü ïîïðîñâåùàòü ýñêóëàïîâ õðåíîâûõ ?
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #10  
Ñòàðûé 12.07.2012, 20:20
Andrii_Z Andrii_Z âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 03.06.2012
Ãîðîä: Kyiv
Ñîîáùåíèé: 21
Andrii_Z *
È â ìûñëÿõ íå áûëî...

ß ïðîñòî â øîêå ñ ñåãîäíåøíåãî ïîñåùåíèå èíñòèòóòà ðåïðîäóêòèâíîé ìåäèöèíû, ãäå äàæå íå àíäðîëîã, à ãèíåêîëîã ñêàçàëà, ÷òî íóæíî ñðàçó íà ÈÊÑÈ, à ëå÷èòü ñìûñëà íåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #11  
Ñòàðûé 12.07.2012, 20:27
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,412
Ïîáëàãîäàðèëè 33,243 ðàç(à) çà 31,592 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Andrii_Z Ïîñìîòðåòü ñîîáùåíèå
À âîò èíòåðåñíî, íà ïðîñòîðàõ ýêñÑÑÑÐ, êòî íèáóäü åñòü íà íàó÷íîì ôðîíòèðå ïî èññëåäîâàíèÿì ìóæñêîãî áåñïëîäèÿ?
Urologiia. 2012 Jan-Feb;(1):47-51.
[Effects of L-carnitine on ejaculate parameters in males from infertile couples].
[Article in Russian]
Galimov ShN, Gromenko DS, Galimova ÉF, Gromenko IuIu, Iskhakov IR.
The aim of our investigation was detection of molecular mechanisms of an antioxidant action of L-carnitine (a transmembrane carrier of long-chain fatty acids) in idiopathic pathospermia. We treated 60 males from infertile couples with karniton (1 g/day). L-carnitine impact on ejaculate antioxidant status was assessed by registration of chemiluminescence and total antioxidant activity by colorimetric method according to changes in the color of ABTS chromogen. High dose-dependent antioxidant activity of the drug was found in testing on model systems in vitro. In vivo trials showed that patients given L-carnitine demonstrated a significant increase of the number of mobile spermatozoa of A category, positive changes in parameters of luminal-dependent and Fe2+ induced chemiluminescence of ejaculate in elevated antioxidant capacity of spermoplasma. After karniton treatment of the husbands 23% of their wives got pregnant. The treatment efficacy may be due to normalization of antioxidant status of ejaculate.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #12  
Ñòàðûé 12.07.2012, 21:32
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,285
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,625 ðàç(à) çà 32,699 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èíûìè ñëîâàìè , íà ñàìîì äåëå ó Âàñ âîïðîñ î ëå÷åíèè áåñïëîäíîé ïàðû, â êîòîðîé âûÿâëåí ìóæñêîé ôàêòîð ?
Íó òàê è çàäàéòå ýòîò âîïðîñ
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 19:25.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.